Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy—experience of 10 Romanian HD centers

• DOI: 10.1007/s11255-023-03587-0
• Publication Date: 2023-04-06T17:02:42Z
• Authors: Luciana Marc; Adelina Mihaescu; Raluca Lupusoru; Oana Schiller; Flaviu Bob; Lazar Chisavu; Felix Bende; Roxana Sirli; Adalbert Schiller
• Keywords: Nephrology; Hepatitis C; Renal replacement therapy

End-stage kidney disease patients (ESKD) receiving hemodialysis (HD) are at a greater risk of hepatitis virus (HV) infections due to the invasive nature procedures, frequent hospital stays and surgeries, as well immune deficiency status ESKD.This study was reassess prevalence in HD population Romania after 5 years oral DAAs therapy assess impact on patients' outcomes two cohorts (2015 2019).We compared ESKD treated with 10 centers from historical regions 2015 (n = 1401, Mean age 59.7 ± 12.92 years) same 2019 1698, mean 61 12.93 years). All went through for more than 90 days.The cohort were significantly older (p 0.005), had longer duration < 0.0001), vascular calcifications 0.015); crude one-year mortality rate did not differ (9.9 vs. 10.7%, p 0.46). The HBV infection between (4.7% 4.8, 0.604) but HCV decreased (16.9 10.5%, 0.0001).After 15 nationwide prevention program HV treatment Romania, change significantly, however, it still remained high.